BC Extra | Jan 7, 2020
Company News

Management tracks: Rhythm, Mirati, Aura, IFM, a16z, Cambrex, Alzheon and more

Rare metabolic disease company Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) said Keith Gottesdiener will step down as CEO, president and a board member after more than eight years. He will stay on through the company’s submission of...
BC Extra | Nov 19, 2019
Company News

Alkermes expands CNS pipeline with Rodin acquisition

A mix of preclinical and clinical data spurred Alkermes' takeout of Rodin, which adds HDAC-targeting programs to the biotech's CNS arsenal. The deal comes less than a month after Alkermes plc (NASDAQ:ALKS) restructured to maintain...
BioCentury | May 4, 2019
Product Development

Amyloid: how did we get here and what can we learn?

Unlike any other theory in drug development, the amyloid hypothesis of Alzheimer’s disease has maintained an almost cult-like following, despite two decades littered with a long line of late-stage failures and not a single success....
BC Extra | Oct 30, 2018
Company News

Management tracks: Blueprint, Clovis

Ahead of the anticipated 2019 launch of avapritinib, Blueprint Medicines Corp. (NASDAQ:BPMC) hired Christina Rossi into the newly created role of chief commercial officer. She was the multiple sclerosis business unit head of North America...
BioCentury | May 4, 2018
Emerging Company Profile

Needling out Alzheimer’s

United Neuroscience Ltd.’s pipeline comprises immunotherapeutic vaccines that selectively stimulate B cell responses against endogenous neurotoxic proteins. Its lead candidate UB-311 is an anti-beta amyloid vaccine for Alzheimer’s disease designed to improve cognition while avoiding...
BC Extra | Sep 25, 2017
Company News

Management tracks: TapImmune, Camel-IDS, Arvinas

Immuno-oncology company TapImmune Inc. (NASDAQ:TPIV) named Peter Hoang president and CEO. He was SVP of business development and strategy at Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM). Cancer company Camel-IDS N.V. (Brussels, Belgium) named Ruth Devenyns CEO, a...
BioCentury | Aug 18, 2017
Finance

For sale or rent

Vicarius Pharma AG is fielding a team of experienced regulatory and commercial executives to give U.S. biotechs an option to retain more of the value of their products in Europe. On Aug. 14, Vicarius said...
BC Week In Review | Aug 18, 2017
Financial News

Vicarius raises $21.8M in series A

Commercialization company Vicarius Pharma AG (Kuessnacht, Switzerland) raised $21.8 million in a series A round on Aug. 14. CEO of Patheon N.V. (NYSE:PTHN) James Mullen was an investor in the round, and is chairman of...
BC Extra | Aug 15, 2017
Financial News

Vicarius raises $21.8M in series A

Vicarius Pharma AG (Kuessnacht, Switzerland) raised $21.8 million in a series A round. CEO of Patheon N.V. (NYSE:PTHN) James Mullen was an investor in the round, and is chairman of Vicarius' board. The newco partners...
BC Week In Review | Mar 2, 2017
Company News

Perrigo, Royalty Pharma deal

Perrigo will divest its royalty stream rights for multiple sclerosis drug Tysabri natalizumab to Royalty Pharma for $2.2 billion up front. Biogen Inc. (NASDAQ:BIIB, Cambridge, Mass.) markets the humanized mAb against integrin alpha(4) . Perrigo is...
Items per page:
1 - 10 of 2252
BC Extra | Jan 7, 2020
Company News

Management tracks: Rhythm, Mirati, Aura, IFM, a16z, Cambrex, Alzheon and more

Rare metabolic disease company Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) said Keith Gottesdiener will step down as CEO, president and a board member after more than eight years. He will stay on through the company’s submission of...
BC Extra | Nov 19, 2019
Company News

Alkermes expands CNS pipeline with Rodin acquisition

A mix of preclinical and clinical data spurred Alkermes' takeout of Rodin, which adds HDAC-targeting programs to the biotech's CNS arsenal. The deal comes less than a month after Alkermes plc (NASDAQ:ALKS) restructured to maintain...
BioCentury | May 4, 2019
Product Development

Amyloid: how did we get here and what can we learn?

Unlike any other theory in drug development, the amyloid hypothesis of Alzheimer’s disease has maintained an almost cult-like following, despite two decades littered with a long line of late-stage failures and not a single success....
BC Extra | Oct 30, 2018
Company News

Management tracks: Blueprint, Clovis

Ahead of the anticipated 2019 launch of avapritinib, Blueprint Medicines Corp. (NASDAQ:BPMC) hired Christina Rossi into the newly created role of chief commercial officer. She was the multiple sclerosis business unit head of North America...
BioCentury | May 4, 2018
Emerging Company Profile

Needling out Alzheimer’s

United Neuroscience Ltd.’s pipeline comprises immunotherapeutic vaccines that selectively stimulate B cell responses against endogenous neurotoxic proteins. Its lead candidate UB-311 is an anti-beta amyloid vaccine for Alzheimer’s disease designed to improve cognition while avoiding...
BC Extra | Sep 25, 2017
Company News

Management tracks: TapImmune, Camel-IDS, Arvinas

Immuno-oncology company TapImmune Inc. (NASDAQ:TPIV) named Peter Hoang president and CEO. He was SVP of business development and strategy at Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM). Cancer company Camel-IDS N.V. (Brussels, Belgium) named Ruth Devenyns CEO, a...
BioCentury | Aug 18, 2017
Finance

For sale or rent

Vicarius Pharma AG is fielding a team of experienced regulatory and commercial executives to give U.S. biotechs an option to retain more of the value of their products in Europe. On Aug. 14, Vicarius said...
BC Week In Review | Aug 18, 2017
Financial News

Vicarius raises $21.8M in series A

Commercialization company Vicarius Pharma AG (Kuessnacht, Switzerland) raised $21.8 million in a series A round on Aug. 14. CEO of Patheon N.V. (NYSE:PTHN) James Mullen was an investor in the round, and is chairman of...
BC Extra | Aug 15, 2017
Financial News

Vicarius raises $21.8M in series A

Vicarius Pharma AG (Kuessnacht, Switzerland) raised $21.8 million in a series A round. CEO of Patheon N.V. (NYSE:PTHN) James Mullen was an investor in the round, and is chairman of Vicarius' board. The newco partners...
BC Week In Review | Mar 2, 2017
Company News

Perrigo, Royalty Pharma deal

Perrigo will divest its royalty stream rights for multiple sclerosis drug Tysabri natalizumab to Royalty Pharma for $2.2 billion up front. Biogen Inc. (NASDAQ:BIIB, Cambridge, Mass.) markets the humanized mAb against integrin alpha(4) . Perrigo is...
Items per page:
1 - 10 of 2252